Regarding the New Wording of Draft Resolutions for the General Meeting of Shareholders Convened on 30 June 2025

Dizal’s ZEGFROVY® (sunvozertinib) Receives FDA Accelerated Approval as the Only Targeted Oral Treatment for Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

ASIA’S 50 BEST BARS 2025 REVEALS THE ESTABLISHMENTS RANKED ON THE EXTENDED 51-100 LIST

Blokees Becomes Exclusive Strategic Partner of “Journey of Light: A Glimpse into Ultraman’s 60th Anniversary” Exhibition

First AML expands Tranche 2 leadership in Australia following major client wins across law and real estate

ASIA’S 50 BEST BARS 2025 REVEALS THE ESTABLISHMENTS RANKED ON THE EXTENDED 51-100 LIST

Lake Chelan Health enters into Prime Vendor agreement with Medline